Loading…

Shofu Inc.7979.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties
Momentum leader 82
Mkt cap
$510M
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$1.41M
20-day average traded
Fwd P/E
13.2×
forward earnings
ROIC−WACC
+4.5 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Next earnings
84 days
10 Feb 2027
Close · JPY¥2,272
1D+1.4%
1W+2.3%
1M+0.7%
3M-3.9%
6M+31.9%
YTD+24.5%
1Y+21.6%
ATR %2.9%
52w lowhigh6.1% off high

What Shofu does

Employees: 1,462

Shofu at a glance

Size Shofu (7979.T) is a Japan Health Care company (Medical Specialties) with a market value of $510M, the 1064th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,272 on 18 Nov 2026.

Performance Over six months the shares gained 31.9%, against -19.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 8.7% over the last twelve months (peer median +6.3%); the operating margin is 13.8% (peer median 2.2%).

Valuation It trades at 13.2× forward earnings against a peer median of 23.0× (2nd cheapest of 9).

Capital Return on invested capital runs 4.5 points above its cost of capital (5.6% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 20267979.T 129Peer median 82
Six months, rebased to 100: Shofu against the median of its 20 peers (local-currency closes).

Shofu financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥42.3B¥40.0B¥38.7B¥35.1B¥31.7B
Revenue growth—+3%+10%+11%—
Gross profit¥25.1B¥23.7B¥23.0B¥21.0B¥18.7B
EBITDA¥7.21B¥6.44B¥6.45B¥5.88B¥4.80B
Net income¥6.23B¥4.89B¥4.32B¥3.66B¥3.14B
Free cash flown/a-¥62.0M¥2.22B¥1.47B¥1.62B
Capital expendituren/a¥3.60B¥1.32B¥1.71B¥1.63B
Total debt¥1.24B¥257M¥213M¥457M¥1.34B

Quarterly statements and history in the cockpit →

Shofu competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%300639AVR688075NNNN300439688298688580MEDXRCELMYGN603520ZJYL002932605369CEVI300869ANGO7979.T6-month return →1-month return →
Up and to the right = strong over both horizons. Shofu is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×60×300639688580MEDX603520688606301033605369CEVI7979.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shofu is the large dot.

Shofu competitors and peer comparison

How Shofu compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shofu against its 20 peers (data as of 18 Nov 2026)
Measure7979.TPeer medianRank in peer set
1-month return+0.7%-5.8%4th highest of 21
6-month return+31.9%-19.1%5th highest of 21
Distance from 52-week high-6.1%-40.9%2nd highest of 21
Revenue growth (TTM)+8.7%+6.3%8th highest of 21
Operating margin13.8%2.2%5th highest of 21
Forward P/E13.2×23.0×2nd cheapest of 9
ROIC minus cost of capital+4.5 pp-2.2 pp3rd highest of 18
EV / EBITDA9.6×n/a—
Net debt / EBITDA-1.7×-2.1×3rd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shofu 7979.TJapan$510M+32%+9%14%13.2×n/an/a
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%57.3×0.4%-13.2%
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%n/an/an/a
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%n/a30.8%-18.6%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%n/a6.0%-7.7%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%n/an/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%19.7×20.1%+4.2%
medmix MEDX.SWSwitzerland$494M+11%-7%6%19.4×4.5%+5.0%
AVITA Medical RCELUnited States$529M+290%+17%-34%n/an/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%n/an/an/a
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%25.8×n/an/a
Jin Medical International ZJYLUnited States$532M+47%-14%2%n/an/an/a
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%6.9×-6.5%-4.3%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%22.4×4.3%+24.4%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%23.5×10.2%+6.5%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%n/a55.3%-4.7%
CellaVision CEVI.STSweden$477M+64%+2%23%32.6×7.1%+10.0%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%n/a15.0%-19.8%
AngioDynamics ANGOUnited States$476M-4%+8%-6%n/an/an/a

Questions

Which companies are Shofu's closest peers?
The cockpit's peer set: Guangdong Hybribio Biotech (300639.SZ), Anteris Technologies Global (AVR), Assure Tech (Hangzhou) (688075.SS), Anbio Biotechnology (NNNN), MedicalSystem Biotechnology (300439.SZ), Zhejiang Orient Gene Biotech (688298.SS), Nanjing Vishee Medical Technology (688580.SS), medmix (MEDX.SW).
Is Shofu expensive compared with its peers?
On forward p/e it trades at 13.2× against a peer median of 23.0×, 2nd cheapest of 9 in its peer set.
How has Shofu stock performed?
Over six months to 18 Nov 2026 the shares returned +31.9% against -19.1% for the median peer; over one year +21.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.